VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 158 filers reported holding VERVE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $106 | -63.9% | 21,755 | -1.7% | 0.00% | – |
| Q1 2024 | $294 | -2.6% | 22,130 | +2.2% | 0.00% | – |
| Q4 2023 | $302 | -1.0% | 21,651 | -6.0% | 0.00% | – |
| Q3 2023 | $305 | -28.7% | 23,033 | +0.9% | 0.00% | -100.0% |
| Q2 2023 | $428 | +18.9% | 22,834 | -8.7% | 0.00% | – |
| Q1 2023 | $360 | -39.4% | 24,998 | -18.5% | 0.00% | -100.0% |
| Q4 2022 | $594 | -99.9% | 30,685 | +0.1% | 0.00% | -50.0% |
| Q3 2022 | $1,053,000 | +155.6% | 30,642 | +13.7% | 0.00% | +100.0% |
| Q2 2022 | $412,000 | -32.8% | 26,961 | +0.4% | 0.00% | 0.0% |
| Q1 2022 | $613,000 | -43.7% | 26,847 | -9.0% | 0.00% | 0.0% |
| Q4 2021 | $1,088,000 | +41.5% | 29,507 | +80.4% | 0.00% | 0.0% |
| Q3 2021 | $769,000 | – | 16,359 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,008,809 | $37,665,169 | 23.26% |
| Alphabet Inc. | 10,549,086 | $197,795,362 | 10.63% |
| Casdin Capital, LLC | 2,360,571 | $44,260,706 | 3.87% |
| MPM BioImpact LLC | 857,940 | $16,086,375 | 3.24% |
| Redmile Group, LLC | 1,061,960 | $19,911,750 | 0.76% |
| Novo Holdings A/S | 500,000 | $9,375,000 | 0.72% |
| ARK Investment Management | 5,150,851 | $96,578,455 | 0.64% |
| Avidity Partners Management LP | 878,600 | $16,473,750 | 0.58% |
| Nikko Asset Management Americas, Inc. | 2,185,857 | $40,941,102 | 0.43% |
| Cormorant Asset Management, LP | 350,000 | $6,562,500 | 0.37% |